Irritative voiding symptoms (e.g. increased frequency and urgency) occur in many common pathologic conditions such as urinary tract infections and bladder outlet obstruction, and these conditions are well-established to have underlying inflammation that directly triggers these symptoms. However, it remains unclear as to how such diverse stimuli individually generate a common inflammatory process. Jürg Tschopp provided substantial insight into this conundrum when, working with extracts from THP-1 cells, he reported the existence of the inflammasome. He described it as a structure that senses multiple diverse signals from intracellular/extracellular sources and pathogens and triggers inflammation by the maturation and release of the pro-inflammatory cytokines interleukin-1β and interleukin-18. Recently, many of these sensors were found in the bladder and the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3, has been shown to be a central mediator of inflammation in several urological diseases. In this review, we introduce the nucleotide-binding domain, leucine-rich-containing family, pyrin domaincontaining-3 inflammasome, highlight its emerging role in several common urologic conditions, and speculate on the potential involvement of other inflammasomes in bladder pathology.
Introduction
The bladder lumen is a hostile environment. Under normal conditions chemicals or microbes in the urine are denied entry into the bladder wall by a glycosaminoglycan layer at the luminal surface of the urothelium. If this layer is compromised by invasive uropathogens, mechanical trauma (stones, catheters, etc.) or idiopathically in the case of interstitial cystitis, a host of potentially dangerous components gain access to the underlying tissue. Even with an intact barrier, the urothelium may be significantly altered in certain pathological conditions by physical changes such as elevated intravesical pressure, overstretch of tissues, hypoxia/reperfusion or products of metabolic dysregulation. The near ubiquitous response to this plethora of insults is the appearance of an inflammatory state. Despite the pervasive inflammation, there has been no clear understanding of the mechanism by which such diverse factors could trigger this common response. Inflammation in response to a wide range of agents is not unique to the bladder and in 2002 Jürg Tschopp began to shed light on this quandary in immune cells when his group discovered the existence of the inflammasome; a multimeric structure that senses diverse stress signals and triggers inflammation by the maturation and release of the pro-inflammatory cytokines interleukin-1β (IL-1β) and . Recently, the inflammasome has also emerged as a central mediator linking bladder insults to bladder inflammation and, ultimately, to bladder pathology [2, 3] .
Introduction to the Inflammasome
After the mechanical catharsis of micturition and the barrier provided by the glycosaminoglycan layer, the bladder's next line of defense is the innate immune system and the triggering of inflammation [4] . Cells that comprise the innate system rely on a set of receptors, collectively known as pattern recognition receptors, to detect relevant signals and initiate a response. These receptors are expressed by many different cell types including fibroblasts, myeloid immune cells, and epithelial cells [5] . The pattern recognition receptors are classified into 5 families: toll-like receptors (TLRs), C-type lectin receptors, retinoic acid-inducible gene-I (RIG-1)-like receptors, absent in melanoma 2 (AIM2)-like receptors, and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) [6] .
NLRs are located intracellularly where they recognize 2 different types of signals, pathogen-associated molecular patterns (PAMPs) and danger (or damage) associated molecular patterns (DAMPs) [6] . PAMPs include common bacterial components and known virulence factors, such as lipopolysaccharide (LPS), flagellin, and hemolysins [5] . DAMPs are typically released by stressed, damaged or dying cells and include adenosine triphosphate (ATP), uric acid crystals, high-mobility group box 1, and heat-shock proteins [6] . A list of DAMPs and PAMPs particularly relevant to the urologic system is shown in table 1.
The NLR protein family is large and diverse with over 20 known members in humans, many of which may contribute to the innate immune response in different ways. For example, some NLRs (NOD1, NOD2) stimulate transcription of NF-κB-regulated genes [7] whereas others assist the adaptive immune response by triggering transcription of major histocompatibility class II genes for antigen-presenting cells [8] . However, NLRs are best known for those that assemble into cytosolic multi-protein complexes called inflammasomes, which are typically named for the NLR involved. For example the inflammasome formed with nucleotide-binding domain, leucine-rich-containing family, pyrin domaincontaining-3 (NLRP3) is known simply as the NLRP3 inflammasome. Formation of the inflammasome triggers the cleavage of pro-caspase-1 into active caspase-1. Caspase-1 cleaves pro-IL-1β and pro-IL-18 into their active forms (IL-1β and IL-18) along with gasdermin D, which triggers pyroptosis [9, 10] , a pro-inflammatory form of cell lysis. Pyroptosis in turn releases the mature IL-1β and IL-18 as well as intracellular DAMPs such as ATP, uric acid, and high-mobility group box 1 that further propagate inflammation [11, 12] . Additionally, some other PPRs can form inflammasomes such as RIG-1 and AIM2 [13, 14] .
The NLRP3 Inflammasome
The best-studied member of the NLR family is NLRP3, which plays important roles in a wide variety of inflammatory pathologies. Unlike many other NLRs, NLRP3 is activated by both PAMPs and DAMPs [15] [16] [17] making it ideally suited to play a central role in the innate Fig. 1 . Domain structure of the components of the NLRP3 inflammasome. The NLRP3 inflammasome contains 3 components: 1) NLRP3 (the nod-like receptor), 2) ASC, and 3) procaspase-1. NLRP3 consists of 3 separate domains: a C-terminal LRR domain, a NACHT domain and an N-terminal PYD. ASC is composed of a PYD and a CARD, and is the adaptor protein that binds pro-caspase-1. Pro-caspase-1 has a CARD and 2 subunits (p20 and p10) which are cleaved to form active caspase-1 by the inflammasome.
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Inflammasomes in Bladder Pathology 59 immune response. In an early tissue survey of NLRP3 expression, Kummer et al. [18] documented the presence of NLRP3 in the human bladder, and our lab has subsequently confirmed its expression in the rat and localized it to the urothelial layer [19] . The domain structure of the components of the NLRP3 inflammasome is shown in figure 1 and is important to assembly. NLRP3 contains 3 separate domains; an N-terminal pyrin (PYD) domain that mediates homotypic binding, a nucleotide-binding and oligomerization (NACHT) domain that mediates ATP-dependent oligomerization, and a C-terminal leucine-rich repeat (LRR) domain that senses ligand (in the case of NLRP3 probably indirectly). While other NLRs also have caspase recruitment domains (CARDs) as part of their primary sequence, NLRP3 requires an adaptor protein to connect to pro-caspase-1. The adapter is known as apoptosis-associated speck-like protein containing a CARD (ASC) and consists of a PYD and a CARD. Pro-caspase-1 has a CARD and 2 subunits (p20 and p10) that become part of the final enzyme.
Activation of the NLRP3 inflammasome can occur by 3 different pathways termed the 1) canonical 2) noncanonical or 3) alternative pathways [11, [20] [21] [22] [23] [24] [25] . The canonical pathway requires 2 steps: priming and activation. Priming ( fig. 2 ) begins when a DAMP or PAMP binds to a non-NLR receptor (typically a TLR) or there is signaling through endogenous cytokine receptors such as IL-1R and tumor necrosis factor receptor [26] . Signaling through NF-κB initiates production of de novo pro-IL-1β and NLRP3 [15, 26, 27] while signaling through BRCC36 deubiquitinates preexisting NLRP3 [28, 29] , licensing it to form an inflammasome.
Canonical activation of NLRP3 ( fig. 3 ) can be triggered in different models by different DAMPs and PAMPs. Given the large number of agents activating a single target, it seems unlikely to occur by direct ligand binding to NLRP3 and so there has been an intense study to find a common cellular event activating this inflammasome. Reactive oxygen species (ROS) were first proposed to be such an activator [30] , but subsequent studies suggests they may dispensable [31] . Thus, the generation of ROS might best be thought of as a pathway to activation induced by certain DAMPs/PAMPs [32] . Likewise, Ca 2+ signaling was suggested as a general requirement by several studies [33] [34] [35] but that too has been challenged [36] . Currently the prevailing theory is that K + efflux represents a common denominator in the canonical pathway of NLRP3 activation [31, 37, 38] . However, how that may translate to NLRP3 assembly is unknown and K + loss is not excusive to inflammasome activation but is a well-established event in apoptosis as well [39] [40] [41] .
Regardless of the trigger, once assembly is initiated, the catalytic domain of the never in mitosis gene A-related kinase 7 [42, 43] interacts with the LRR domain of NLRP3 causing the NLRP3 to oligomerize through binding of NACHT domains. The NLRP3 oligomer then binds ASC, through homotypic binding of pyrin domains, which forms long filaments that bind multiple molecules of pro-caspase-1 ( fig. 3 depicts only a dimer for simplicity). This large (up to 1 µm) structure is surprisingly sta- Fig. 2 . Priming of the NLRP3 inflammasome in the canonical pathway. The canonical pathway of NLRP3 inflammasome activation requires a priming step. This occurs when a DAMP or PAMP (such as LPS) binds to a non-NLR receptor (such as TLR) or there is signaling though IL-1R or tumor necrosis factor receptor. The effect of this binding leads to further signaling through either NF-κB and/or BRCC36. Signaling through NF-κB leads to production of de novo pro-IL-1β and other components of the NLRP3 inflammasome while signaling through BRCC36 leads to deubiquination of existing NLRP3. Deubiquination then frees NLRP3 to be activated, i.e. "licenses" it for activation.
Inouye/Hughes/Sexton/Purves ble and is often known as an ASC-speck. Typically only one of these form per cell and it incorporates all the ASC in that cell. Holding pro-caspase-1 molecules in close proximity in this speck results in an autocatalytic cleavage process known as induced proximity. This cleaves caspase-1 into its p20 and p10 subunits which associate with an additional set of p20 and p10 subunits to form an active tetramer. Both the active caspase-1 and the CARD domain dissociate from the speck and caspase-1 then cleaves pro-IL-1β and pro-IL-18 into their active forms (IL-1β and IL-18). Caspase-1 also cleaves gasdermin D [10] whose N-terminus is responsible for forming a pore in the cell membrane that results in pyroptosis [44] [45] [46] .
The NLRP3 inflammasome can also be activated by a non-canonical pathway ( fig. 4) where LPS in the cytosol directly binds to the CARD domain of caspase-11 (in rodents; caspase-4 and caspase-5 in humans) [9, 47, 48] . This triggers the oligomerization and activation of caspase-11, which can directly cleave gasdermin D and cause pyroptosis, without promoting inflammasome for- Fig. 3 . Activation of the NLRP3 inflammasome in the canonical pathway. The second step of the canonical pathway is activation. DAMPs and PAMPs trigger this step and lead to activation of the NLRP3 inflammasome. Proposed cellular events involved include ROS, Ca 2+ signaling, and, most likely, K + efflux. Regardless, NLRP3 inflammasome assembly is initiated and the catalytic domain of the never in mitosis gene a-related kinase 7 interacts with the LRR domain of NLRP3 causing oligomerization through binding of NACHT domains (the figure depicts only a dimer for simplicity). This leads to NLRP3 binding to ASC and ASC in turn binding to procaspase-1. Pro-caspase-1 molecules in close proximity lead autocatalytic cleavage of pro-caspase-1 to caspase-1 (induced proximity). Activated caspase-1 then cleaves pro-IL-1β and pro-IL-18 into their active forms (IL-1β and IL-18). Caspase-1 also cleaves gasdermin D whose N-terminus is responsible for forming a pore that results in pyroptosis and the release of IL-1β and IL-18. Inflammasomes in Bladder Pathology 61 mation or cytokine production. Caspase-11 can also lead to the release of ATP, which can stimulate K + loss and the assembly of the NRP3 inflammasome, leading to the release of IL-1β and Il-18. Like the canonical pathway, K + efflux is also characteristic of the noncanonical pathway. The importance and uniqueness of the non-canonical pathway have been highlighted by decreased mortality in caspase-11-deficient mice exposed to systemic administration of LPS [47, 49] .
There is a third mechanism of NLRP3 activation (fig. 5), known currently as the alternative pathway that has been shown in human monocytes, although the extent of its deployment across cell types has not been thoroughly examined [23] [24] [25] 50] . Similar to the canonical pathway, the alternative pathway relies on LPS binding to TLR4 to upregulate NLRP3 and pro-IL-1β production. However, unlike the canonical pathway, the efflux of K + is not required [50] . Instead, TLR4 signaling leads to toll/ interleukin-1 receptor-domain-containing adapter-inducing interferon-β, receptor-interacting protein kinase 1, Fas-associated protein with death domain, and caspase-8 acting downstream to activate the NLRP3 inflammasome leading to cleavage of pro-IL-1β to IL-1β. Even though the inflammasome requires ASC and caspase-1 for this cleavage, there is no evidence for ASC speck formation or pyroptosis in this pathway [23, 25] .
Urologic Pathology Dependent on Inflammasomes
The NLRP3 inflammasome was first discovered to mediate bladder inflammation in a cyclophosphamide-induced hemorrhagic cystitis model [51] . Since that time, inflammasomes have been implicated in both sterile and Inouye/Hughes/Sexton/Purves infectious cystitis, as well as malignancy. The following sections will discuss the role of inflammasomes in cyclophosphamide-induced hemorrhagic cystitis, bladder outlet obstruction (BOO), urinary tract infections (UTI), and bladder cancer.
Cyclophosphamide-Induced Hemorrhagic Cystitis
Cyclophosphamide is a widely used chemotherapeutic agent and acrolein, the metabolic byproduct of cyclophosphamide, is stored in the bladder prior to excretion where it damages the urothelium and can cause hemorrhagic cystitis. Fortunately, its occurrence in the patient population has been minimized primarily through the use of super hydration and 2-mercaptoethane sulfonate sodium, which chelates the acrolein in the urine and masks its toxic effects. However, it remains a useful experimental model to study the mechanisms of sterile bladder inflammation. Suggestive of a role for the inflammasome in this model, Smaldone et al. [52] reported an increase in urinary IL-1β and IL-18. Moreover, used the IL-1 receptor antagonist anakinra in mice to directly demonstrate a causative role for IL-1β. Recently, our group inhibited NLRP3 in rats using glyburide, an FDA-approved diabetic medication and known inhibitor of the NLRP3 inflammasome [56] . Addition of this inhibitor diminished the changes associated with irritative voiding (increased frequency, decreased volume) along with reducing IL-1β and IL-18 levels and suppressing inflammation [51] . Haldar et al. [57] further refined the underlying mechanism by demonstrating that acrolein oxidizes mitochondrial DNA while epigenetically silencing DNA repair enzymes. The oxidized DNA then triggers NLRP3 inflammasome activation. Furthermore, IL-1β, acting downstream through insulin-like growth factor, induces bladder smooth muscle hyperplasia, a well-known change in this model that could be a contributor to the irritative voiding changes [57] . Taken together the findings of several investigators demonstrate that the NLRP3 inflammasome is critical in mediating biochemical, histological, and physiological inflammation during cyclophosphamide-induced hemorrhagic cystitis. BOO BOO is most often the result of benign prostatic hyperplasia (BPH) in older men, but may also occur after urethral stricture disease, pelvic organ prolapse, neurological trauma/disease, or in children with posterior urethral valves. BOO causes physical changes in the bladder, which leads to chronic inflammation [58] [59] [60] [61] [62] [63] that evokes clinically bothersome, irritative voiding symptoms that are difficult to treat using available therapies. Our lab has explored the role of the NLRP3 inflammasome in a rat model of BOO in which the animals are treated with NLRP3 inhibitor glyburide before and during development of this disorder. We found that NLRP3 is activated in the acute period of BOO and is responsible for triggering the resulting inflammation and bladder hypertrophy [62] . Urodynamic studies of BOO rats demonstrated that glyburide prevented the increase in urinary frequency and decrease in void volume characteristic of irritative voiding symptoms seen during BOO in patients. Treatment with glyburide also led to a longer duration of void- The alternative pathway is the third mechanism of NLRP3 inflammasome activation. Similar to the canonical pathway's priming step, LPS binds to TLR4 that leads to upregulation of NLRP3 and pro-IL-1β through the NF-κB pathway. However, instead of the K + efflux, NLRP3 inflammasome activation relies on toll/interleukin-1 receptor-domain-containing adapter-inducing interferon-β, receptor-interacting protein kinase 1, Fas-associated protein with death domain, and caspase-8 that are upregulated by the TLR4 signaling.
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ing, leading us to conclude that blocking inflammation allowed the detrusor muscle to maintain a longer, stronger contraction, not surprising given that non-inflamed muscles can sustain a contraction longer then inflamed ones. Strong genetic evidence for the importance of the NLRP3/IL-1β pathway in BOO pathology was also provided by Kanno et al. [64] who found that inflammatory endpoints in obstructed mice were diminished in IL-1β
strains. Inflammasomes, and NLRP3 in particular, can have very specific activating stimuli, although the exact mechanism of NLRP3 activation in response to BOO has not been defined. We propose that at least 3 potential inflammasome-activating insults occur repeatedly following obstruction. As shown in figure 6, those insults are hypoxia/reperfusion, increased pressure, and repetitive stretching. Both hypoxia and reperfusion are known to trigger the release of ROS and ROS is a well-known trigger for NLRP3 [11, 21, 65] , if not a universal event. Due to incomplete emptying, inflammation, hypertrophy, and more, obstructed bladders are greatly enlarged compared to controls and undergo excessive distension during filling. This stretch reduces the diameter of blood vessels within the bladder wall, reducing blood flow and creating a mildly hypoxic environment [66] . Micturition relieves this partial occlusion resulting in reperfusion which brings a bolus of oxygen into the tissue that drives a burst of oxidative phosphorylation in the mitochondria and a surge of ROS, a well-known trigger for NLRP3 [11, 21, 65] . 6 . NLRP3 inflammasome activation in BOO. The NLRP3 inflammasomes is thought to be activated by at least 3 repetitive insults during BOO: hypoxia/reperfusion, high pressure and increased stretching. Hypoxia/reperfusion leads to production of ROS, a known trigger for the inflammasome. Increased pressure and repetitive stretch both release ATP, a known NLRP3 DAMP. Furthermore, bladder stretching releases acetylcholine that can act back on cholinergic receptors to trigger release of more ATP. The increase in extracellular ATP caused by pressure, stretch, and acetylcholine can drive yet another positive feedback loop known as ATP-dependent ATP release. The result is a tremendous amount of extracellular ATP, which then serves as a trigger for NLRP3 activation. 
NLRP3

Denervation
The potential also exists for NLRP3 to be activated by both increased pressure and stretch, which may exert their effects additively or synergistically through the release of ATP; a potent activator of NLRP3 [16, 67] . Compared to a normal bladder, an obstructed bladder has a much higher pressure during micturition as the detrusor contracts with greater force to overcome the obstruction. Recently, Nagatomi's laboratory has used urothelial cells in culture to demonstrate that exposure to increased hydrostatic pressure directly stimulates ATP release [68] and NLRP3 activation [69] . The use of purinergic receptor antagonists demonstrated that the released ATP is directly responsible for triggering inflammasome activation (Jiro Nagatomi, personal communication, May 20, 2017) suggesting that pressure-induced release of ATP may play an important part in triggering NLRP3-mediated inflammation during BOO. Due to decreased bladder compliance secondary to BOO, the bladder also stretches much more during the storage phase, and increased stretch has been well-established in the literature to trigger the release of ATP [70] [71] [72] [73] [74] . Currently, no studies have investigated the ability of stretch to activate the NLRP3 inflammasome, although it is likely to be rich fodder for future studies. In addition to these 2 ATP-releasing mechanisms, the literature suggests the presence of an amplifying loop within the urothelia. Increased stretch stimulates the release of acetylcholine in addition to ATP [71, [75] [76] [77] . While this acetylcholine may have effects on nearby nerves, it can also act on cholinergic receptors in the urothelia to trigger release of more ATP [78, 79] . The increase in extracellular ATP caused by pressure, stretch, and acetylcholine can drive yet another positive feedback loop known as ATP-dependent ATP release [80] . The ultimate result is a substantial amount of ATP just outside the cell membrane. All of this ATP from the individual cell would be joined by ATP released from neighboring cells undergoing pyroptosis, magnifying this feed forward loop and propagating inflammation during BOO. While additional studies need to be performed to quantify the impact of such a feed forward loop, the literature clearly indicates that repetitive insults associated with BOO trigger an ongoing inflammatory process mediated by NLRP3 that evokes negative downstream events such as irritative voiding and fibrosis.
The harmful effects of an acute episode of BOO can typically be alleviated by simply removing the obstruction. However, in patients with chronic BOO (such as seen with BPH) de-obstruction is not always successful in restoring normal bladder function because the bladder has become decompensated and thus dysfunctional.
The changes underlying decompensation are complex but certainly involve at least 2 major, potentially irreversible, changes to the bladder; fibrosis and denervation. Numerous studies in pulmonary, cardiac, and renal systems have demonstrated a link between the NLRP3 inflammasome and the induction of fibrosis [81-84] and we have recently shown a similar link in the bladder [61] . In those studies inhibition of NLRP3 with glyburide or IL-1β with a receptor antagonist (anakinra) blocked the appearance of fibrotic endpoints [85] . In vitro, urothelial cells exposed to IL-1β responded by producing collagens and cells harvested from BOO rats secreted more collagen than those taken from control animals. These findings suggest the existence of an IL-1β-mediated profibrogenic positive feedback loop within the urothelia that is active during BOO [61] .
Loss of bladder nerve density during BOO has been found in many different species including man [86] [11, 21, 65] . In our rat model of BOO, inhibiting NLRP3 (glyburide) or blocking the IL-1 receptor (anakinra) attenuated the loss of neurons while in vitro experiments demonstrated a direct apoptotic effect of IL-1β on pelvic ganglionic neurons, suggesting 1 mechanism of BOO-induced denervation may be NLRP3/IL-1β triggered apoptosis. The combination of our studies on fibrosis and denervation suggest NLRP3 may be an important therapeutic target for preventing bladder deterioration and decompensation during the progression of BOO.
While the most common cause of BOO is BPH, it is interesting that BPH itself may be a result of inflammasome activation [93] . Clearly, infectious prostatitis has the potential to activate inflammasomes through PAMPs, but not all cases of prostatitis are infectious nor does infectious prostatitis necessarily cause BPH. Recently, Kashyap et al. [94] demonstrated that injection of formalin into the prostate upregulated NLRP1, caspase-1, and the cytokines IL-1β and IL-18. Thus, inflammasomes may mediate both infectious and sterile prostatitis, leading to BPH, BOO, and activation of NLRP3 within the bladder, eventually causing all of the deleterious results just discussed. Intriguingly, the main NLR involved in the prostate appears to be NLRP1, not NLRP3. NLRP1 has also been found in the bladder where its role remains unknown [95] .
Uropathogenic E. coli UTIs
UTIs are the second most common forms of infection behind only the common cold and IL-1β is one of the first cytokines detected at the onset, suggesting an early role of inflammasomes in infectious cystitis [96] . While UTIs can be caused by various viral, mycobacterial, chlamydial, fungal, and schistosomal agents, by far the most common culprits are gram-negative, uropathogenic Escherichia coli (UPEC) [97] . UPEC produce LPS, flagellin, and α-hemolysin, which are wellknown PAMPs that activate NLR inflammasomes in other tissues. Our lab has recently shown that both LPS and flagellin can trigger inflammasome activation when placed in the lumen of the bladder [51] . Moreover, injection of LPS into the bladder wall triggered irritative voiding reminiscent of UTIs and this pathological effect was blocked by glyburide [98] , clearly showing that LPS activation of NLRP3 can evoke a cystitis analogous to what is seen during a UTI. Nagamatsu et al. [99] examined α-hemolysin expression in UPEC and found that α-hemolysin activated NLRP3 and triggered pyroptosis in human urothelia. This leads to exfoliation of urothelial cells, which is presumed to act as a host defense mechanism against UPEC expressing α-hemolysin. This approach is not without its downside however, as exposing the underlying transitional cells can allow the UPEC to penetrate further and form quiescent cellular reservoirs that can lead to chronic cystitis [99] .
Perhaps unsurprisingly, given the nature of hostpathogen interactions, UPEC strains that avoid activation of NLRP3 show increased virulence or asymptomatic colonization [100] . For example, Waldhuber et al. [101] found that UPEC strain CFT073 avoids activation of the NLRP3 inflammasome by expressing Toll/IL-1 receptor-containing protein C (TcpC), a multifunctional protein that inhibits NLRP3 activation by binding both NLRP3 and pro-caspase-1, consequently suppressing the processing and activation of pro-caspase-1. TcpC also blocks signaling through the TLRs necessary for priming of NLRP3. Inhibition of TcpC expression resulted in greater activation of NLRP3 and elevated urinary IL-1β secretion compared to mice infected with wildtype UPEC strains [102] . Thus, NLRP3 may be a central player in the host-pathogen interaction during UPEC UTIs.
Group B Streptococcal UTIs
Inflammasomes have also been implicated in the host response to UTIs by gram-positive bacteria such as Streptococcus agalactiae, a Group B streptococcus (GBS) [103] . Their involvement was suspected when the initial stages of GBS UTIs were found to be characterized by secretion of IL-1β [104] . With uropathogenic GBS, β-hemolysin (a PAMP) activates the NLRP3 inflammasome by causing lysosomal leakage which permits the escape of GBS RNA (another, independent, PAMP) into the cytosol. Transfection of GBS RNA directly into the cytosol of GBS-infected cells increased IL-1β production while, conversely, introduction of RNase into this compartment decreased cytokine secretion [105] . Although bacterial RNA can clearly be important in inflammasome activation, it is not thought that NLRP3 is directly activated by the RNA. It has been hypothesized that the RNA could initiate the recruitment of mitochondrial antiviral signaling protein that mediates membrane damage through ROS production with subsequent release of intracellular K + [106, 107] . As might be expected, NLRP3-mediated inflammation in response to GBS is important for control of the infection. Costa et al. [103] infected mice with GBS and found that those lacking NLRP3 inflammasome components had increased mortality and an elevated GBS burden compared to controls. In another study, mice lacking IL-1 receptors were also found to be more susceptible to GBS infection compared to controls [108] . Finally, as was seen with UPEC [99], activation of NLRP3 results in urothelial exfoliation, exposing deeper layers and resulting in the formation of quiescent reservoirs leading to chronic UTIs. Thus, NLRP3 seems to be in a delicate balance where its activation is necessary for an adequate host response, but may also contribute to chronic colonization or infection. The therapeutic challenge, then, is to modulate the inflammatory response rather than eliminate it so that the advantageous mechanisms are preserved or enhanced while deleterious effects are minimized.
Bladder Cancer
While NLRP3 gene polymorphisms have been associated with melanoma, myeloma, and colorectal cancer [109] [110] [111] , not until recently was there an investigation of the role of inflammasomes in bladder cancer [112] . Poli et al. [112] examined mRNA in urine from human subjects with and without bladder cancer for expression of inflammasome components and cytokeratin 20 mRNA (CK20), a marker of urothelial differentiation that is highly expressed in bladder cancer [113] . They found that compared to healthy controls, patients with bladder cancer on biopsy had an increased expression of NLRP3 and NLR family apoptosis inhibiting protein [NAIP; an important adaptor for the NLR containing a caspase recruitment domain 4 (NLRC4) inflammasome]. In addition, NLRP3 expression was increased in lowgrade tumors, while NAIP expression was increased in high-grade tumors, although the significance of that is unknown. They also saw an increase in NLRP3 gene expression in patients with non-malignant inflammatory lesions on biopsy compared to healthy controls. The group concluded that concurrent analysis of NLRP3 or NAIP expression with CK20 enhanced the sensitivity and specificity of detection of bladder cancer. Therefore, while the mechanism of NLRP3 and NLRC4 inflammasomes in the genesis or proliferation of bladder cancer is unknown, their expression is present and may serve as a potential diagnostic biomarker.
Non-NLRP3 Inflammasomes in the Bladder and Their Potential Roles
NLRP3 is the most studied inflammasome in the bladder and elsewhere. While most bladder pathology has been linked to this inflammasome, other inflammasomes may have potential roles as well. Indeed, many other NLRs that form inflammasomes, along with AIM2 which also forms an inflammasome, have been localized to the urothelia [95] ( fig. 7 ) and thus may be important mediators in bladder inflammatory pathologies through unexplored mechanisms. As the RIG-I inflammasome has not been localized to the bladder urothelium, it was not included in the following section. Table 2 lists the inflammasome-forming PPRs that have been found in the bladder and their known and potential roles in the bladder, which will be discussed in more detail below.
NLRP1 Inflammasome
NLRP1 was the first inflammasome to be described [1] and it plays a role in prostate inflammation [94] . It differs mechanistically from NLRP3 by undergoing an autolytic proteolysis necessary for activation [114] . It has been implicated in the inflammatory response to Bacillus anthracis [115] , but, importantly, it has also been found to respond to muramyl dipeptide, which is a common peptidoglycan in gram positive and negative bacteria [116] . Therefore, the NLRP1 inflammasome may play a role in mediating UTI responses.
NLRP6 Inflammasome
The NLRP6 inflammasome differs from NLRP3 by not only activating proinflammatory cytokines, but by also having the potential to directly downregulate the NF-κΒ and mitogen-activated protein kinase pathways Inflammasomes in Bladder Pathology 67 [117, 118] . NLRP6 is best known for playing two distinct roles in the gut: regulating intestinal microbiota and maintaining the protective mucus layer by facilitating autophagy in intestinal goblet cells [119] . While no PAMP has been found to specifically activate NLRP6 [95] , its roles in the intestine may reflect its potential role in the bladder, which is known to have both asymptomatic biotic flora [120, 121] and significant surface mucus [122] . Intriguingly, its potential role in regulating mucus may make it a useful therapeutic target since dysfunction of bladder surface mucins has been implicated in many bladder disorders including UTIs, calculus formation, radiation cystitis, carcinogenesis, and interstitial cystitis.
NLRP7 Inflammasome
Little is known about the mechanism of activation of NLRP7, but it has been shown to form an inflammasome in response to microbial acylated lipopeptides, common in bacteria such as pseudomonas, which is a prevalent UTI pathogen [123, 124] . Furthermore, NLRP7-produced IL-1β and IL-18 prevent replication of bacteria inside human macrophages [125] . While macrophages are very different from urothelial cells, NLRP7 may play a role in controlling intracellular bacterial communities known to cause chronic cystitis.
NLRP12 Inflammasome
Another poorly understood NLR family member, NLRP12, seems to depend on a functional type III secretion (T3S) system for its activation [126] . As gram-negative bacteria, such as pseudomonas, are known to invade host cells using a T3S system [127] , the NLRP12 inflammasome may play a role in gram-negative UTI. NLRP12 may also be involved in bladder disease associated with idiopathic sterile bladder inflammation, such as interstitial cystitis, for NLRP12 mutations have been associated with hereditary periodic fever syndromes, another unprovoked, self-limited inflammatory attack mediated by IL-1β [128, 129] .
NLRC4 Inflammasome
Even though it has been implicated as a biomarker in bladder cancer, the NLRC4 inflammasome is most commonly known to respond to macrophage invasion by gram-negative bacteria such as Salmonella typhimurium, Legionella pneumophila, and Pseudomonas aeruginosa [130] [131] [132] . Each of these bacteria send their virulence factors, such as flagellin and the inner-rod protein PrgJ, into the cell's cytoplasm through the bacterial T3S system [133] . These bacterial components are recognized in the cytosol by NAIPs, which then facilitate formation of the NLRC4 inflammasome. By drawing a comparison to its role in pulmonary pseudomonal infections [134] , NLRC4 may be a central mediator in pseudomonal UTI. Furthermore, UPECs express aT3S system [135] and therefore may also interact with NLRC4. Finally, our lab has shown that placing flagellin, a well-established activator of NLRC4, in the lumen of the bladder activates caspase-1 activity [51] suggesting this system in the bladder is primed and ready to respond to invading bacteria.
AIM2 Inflammasome
Although AIM2 is not an NLR member, it does form an inflammasome and activate caspase-1. AIM2 is characterized by its Hin200 domains that bind to bacterial and viral double-stranded DNA to trigger inflammasome formation [14] . Therefore, the AIM2 inflammasome may respond to uropathogenic bacteria that release their DNA into the cytoplasm (such as through a T3S system or cytosolic bacteriolysis) or viruses that cause cystitis.
Additional Bladder Disorders
While inflammation is well understood to underlie bladder dysfunction in several common diseases, the role of the inflammasome as the central mediator has only recently been explored. In addition to the conditions just discussed, inflammasomes may be involved in other bladder pathologies like interstitial cystitis and diabetic bladder dysfunction, two common and debilitating diseases associated with bladder inflammation. There is also a potential role for inflammasomes in the inflammation caused by bladder stones. Indeed, monosodium urate is a well-known DAMP and a major component of bladder stones [136] . Our lab has shown that monosodium urate placed in the lumen of the bladder is sufficient to trigger inflammasome activation [51] . By understanding the role of each inflammasome in various pathological conditions, we may be able to target them with therapeutic agents to prevent these diseases and their symptoms.
Potential Treatments
As mentioned, our lab has used glyburide and anakinra, two FDA-approved medications, to inhibit the NLRP3 inflammasome and block the IL-1 receptor, respectively. Although glyburide is very useful experimentally, its hypoglycemic properties would probably limit widespread use in the general clinical population. Anakinra may be a more readily accepted anti-inflammasome medication, since it is already used for treating inflammatory diseases such as rheumatoid arthritis [137] , but its current cost, side effect profile (including immunosuppression), and route of administration (subcutaneous) may limit its use as well. Besides these FDA-approved medications, the Chinese licorice Glycyrrhiza uralensis has been used for centuries as an anti-inflammatory treatment [138] . Recently, one of the active ingredients in this plant, isoliquirtigenin, has been found to be a naturally occurring NLRP3 inhibitor [139] . Not surprisingly, pharmaceutical companies are also developing a wide variety novel medications that target the NLRP3/ IL-1β pathway. These include small molecule inhibitors of NLRP3 such as AC-201 (TWi Biotechnology, Taiwan), MCC950 (Avistron, UK) and Parthenolide (Ashbury Biologicals, Canada) [140] [141] [142] , caspase inhibitors such as Emricasan/IDN-6556 (Conatus Pharmaceuticals, USA) [143] and modified antibodies against IL-1β such as gevokizumab/XOMA 052 (Xoma Corporation, USA), HL 2351/GX P4, Handok, S. Korea) and Canakinumab/ Ilaris/ACZ885 (Novartis, Switzerland).
Conclusion
In both normal and pathological situations, the bladder is a hostile environment and source of many agents that activate inflammasomes to initiate inflammation. While the initial symptoms of inflammation that force a patient to seek a physician are typically irritative voiding patterns and feelings of urinary urgency, long-term or repetitive insults can lead to more dangerous and irreversible outcomes. Further explanation of the inflammasomes and their roles in urologic pathology will greatly enhance our understanding of urologic disease and provide possible therapeutic targets for intervention and management of the debilitating symptoms. 
